Abstract
Through a clinical deep sequencing protocol, Wu and colleagues have identified multiple FGFR fusion proteins in diverse cancers. Pharmacologic inhibition of FGFR suppressed the growth of FGFR fusion-positive tumor models, suggesting that these FGFR fusions are oncogenic drivers and highlighting the use of streamlined clinical sequencing efforts to identify novel, actionable driver oncoproteins in human tumors.
©2013 AACR.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Humans
-
Neoplasms / enzymology
-
Neoplasms / genetics
-
Neoplasms / metabolism*
-
Oncogene Proteins, Fusion / antagonists & inhibitors
-
Oncogene Proteins, Fusion / metabolism*
-
Receptors, Fibroblast Growth Factor / antagonists & inhibitors
-
Receptors, Fibroblast Growth Factor / metabolism*
Substances
-
Oncogene Proteins, Fusion
-
Receptors, Fibroblast Growth Factor